146 related articles for article (PubMed ID: 16809148)
21. Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma.
Gibson MK; Holcroft CA; Kvols LK; Haller D
Oncologist; 2005 Feb; 10(2):132-7. PubMed ID: 15709215
[TBL] [Abstract][Full Text] [Related]
22. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial.
Waters JS; Norman A; Cunningham D; Scarffe JH; Webb A; Harper P; Joffe JK; Mackean M; Mansi J; Leahy M; Hill A; Oates J; Rao S; Nicolson M; Hickish T
Br J Cancer; 1999 Apr; 80(1-2):269-72. PubMed ID: 10390007
[TBL] [Abstract][Full Text] [Related]
23. Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie.
Lutz MP; Wilke H; Wagener DJ; Vanhoefer U; Jeziorski K; Hegewisch-Becker S; Balleisen L; Joossens E; Jansen RL; Debois M; Bethe U; Praet M; Wils J; Van Cutsem E; ;
J Clin Oncol; 2007 Jun; 25(18):2580-5. PubMed ID: 17577037
[TBL] [Abstract][Full Text] [Related]
24. Multi-center phase II trial of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric and gastro-esophageal cancer.
Sun Q; Liu C; Zhong H; Zhong B; Xu H; Shen W; Wang D
Jpn J Clin Oncol; 2009 Apr; 39(4):237-43. PubMed ID: 19264768
[TBL] [Abstract][Full Text] [Related]
25. Multicenter phase II study of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer.
Kim JG; Sohn SK; Song HS; Kwon KY; Do YR; Lee KH; Hyun MS; Ryoo HM; Bae SH; Park KU; Baek JH; Lee WS; Chung JS; Cho GJ; Sohn CH; Jang JS; Chung HY; Yu W
Cancer Chemother Pharmacol; 2007 Nov; 60(6):863-9. PubMed ID: 17333192
[TBL] [Abstract][Full Text] [Related]
26. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma.
Ajani JA; Fodor MB; Tjulandin SA; Moiseyenko VM; Chao Y; Cabral Filho S; Majlis A; Assadourian S; Van Cutsem E
J Clin Oncol; 2005 Aug; 23(24):5660-7. PubMed ID: 16110025
[TBL] [Abstract][Full Text] [Related]
27. The combination of 5-fluorouracil, leukovorin, etoposide, and cisplatin (FLEP) in patients with metastatic esophageal cancer. A single-institution experience.
Jonak C; Raderer M; Zacherl J; Prager G; Troch M; Ba-Ssalamah A; Hejna M
Anticancer Res; 2008; 28(6B):4101-4. PubMed ID: 19192667
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of first-line systemic chemotherapy with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil regimens in locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma: A prospective phase II study from South India.
Babu KG; Chaudhuri T; Lakshmaiah KC; Dasappa L; Jacob LA; Babu M; Rudresha AH; Lokesh KN; Rajeev LK
Indian J Cancer; 2017; 54(1):47-51. PubMed ID: 29199662
[TBL] [Abstract][Full Text] [Related]
29. Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer.
Lee SJ; Cho SH; Yoon JY; Hwang JE; Bae WK; Shim HJ; Chung IJ
Cancer Chemother Pharmacol; 2009 Dec; 65(1):159-66. PubMed ID: 19479256
[TBL] [Abstract][Full Text] [Related]
30. Capecitabine, epirubicin and cisplatin in the treatment of oesophagogastric adenocarcinoma.
Corporaal S; Smit WM; Russel MG; van der Palen J; Boot H; Legdeur MC
Neth J Med; 2006 May; 64(5):141-6. PubMed ID: 16702612
[TBL] [Abstract][Full Text] [Related]
31. A phase II study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as first line therapy for patients with advanced gastric cancer.
Oh SY; Kwon HC; Seo BG; Kim SH; Kim JS; Kim HJ
Acta Oncol; 2007; 46(3):336-41. PubMed ID: 17450469
[TBL] [Abstract][Full Text] [Related]
32. Bimonthly regimen of high-dose leucovorin, infusional 5-fluorouracil, epirubicin and cisplatin (modified ECF) as adjuvant chemotherapy in resected gastric adenocarcinoma.
Unek IT; Unek T; Oztop I; Akman T; Atilla K; Ellidokuz H; Bora S; Sarioglu S; Yilmaz U
Chemotherapy; 2012; 58(3):233-40. PubMed ID: 22832016
[TBL] [Abstract][Full Text] [Related]
33. Weekly infusional high-dose 5-fluorouracil and leucovorin and biweekly cisplatin: a convenient treatment option in advanced gastric cancer.
Kundel Y; Purim O; Figer A; Stemmer SM; Tichler T; Sulkes J; Sulkes A; Brenner B
Med Sci Monit; 2008 Apr; 14(4):CR190-5. PubMed ID: 18376346
[TBL] [Abstract][Full Text] [Related]
34. Phase II study of preoperative paclitaxel/cisplatin with radiotherapy in locally advanced esophageal cancer.
Kim DW; Blanke CD; Wu H; Shyr Y; Berlin J; Beauchamp RD; Chakravarthy B
Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):397-404. PubMed ID: 17097833
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant chemotherapy (ECF regimen) for patients with gastric adenocarcinoma.
Saletti P; Berthold D; Ghielmini M; Zucca E; Fazio N; Goldhirsch A; Cavalli F
Hepatogastroenterology; 2007; 54(75):969-72. PubMed ID: 17591105
[TBL] [Abstract][Full Text] [Related]
36. Weekly high-dose 5-fluorouracil as a 24-h infusion and sodium folinic acid (AIO regimen) plus irinotecan in patients with locally advanced nonresectable and metastatic adenocarcinoma or squamous cell carcinoma of the oesophagus: a phase II trial.
Wolff K; Wein A; Reulbach U; Männlein G; Brückl V; Meier C; Ostermeier N; Schwab SA; Horbach T; Hohenberger W; Hahn EG; Boxberger F
Anticancer Drugs; 2009 Mar; 20(3):165-73. PubMed ID: 19125117
[TBL] [Abstract][Full Text] [Related]
37. Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma.
Lim JY; Cho JY; Oh KJ; Choi SH; Lee SI; Jeung HC
Chemotherapy; 2009; 55(4):200-6. PubMed ID: 19451710
[TBL] [Abstract][Full Text] [Related]
38. Combination chemotherapy with 5-fluorouracil, cisplatin and paclitaxel for pretreated patients with advanced gastric cancer.
Yamaguchi K; Nakagawa S; Yabusaki H; Nashimoto A
Anticancer Res; 2007; 27(5B):3535-9. PubMed ID: 17972514
[TBL] [Abstract][Full Text] [Related]
39. A phase I and II trial of epirubicin, cisplatin, 24-hour infusion 5 fluorouracil and sodium folinate in patients with advanced esophagogastric carcinomas.
Karapetis CS; Cheong KA; Yip D; Strickland AH; Steer C; Marx G; Yip S; Chrystal K; Harper PG
Asia Pac J Clin Oncol; 2010 Dec; 6(4):298-305. PubMed ID: 21114780
[TBL] [Abstract][Full Text] [Related]
40. Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study.
Lenz HJ; Lee FC; Haller DG; Singh D; Benson AB; Strumberg D; Yanagihara R; Yao JC; Phan AT; Ajani JA
Cancer; 2007 Jan; 109(1):33-40. PubMed ID: 17133415
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
